Clinical Trial: Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection

U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07362732) titled 'Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection' on Jan. 14.

Brief Summary: At present, the treatment of multiple myeloma (MM) has evolved from traditional chemotherapy to a comprehensive model that includes targeted drugs, immunotherapy, etc. However, the prognosis of recurrent/refractory MM patients remains severe. For patients who are already resistant to multiple major drugs such as proteasome inhibitors, immunomodulators, and CD38 monoclonal antibodies, the prognosis is particularly poor. B-cell maturation antigen (BCMA) plays a crucial role in regulating B cell ...